Cullinan Therapeutics Gets Buy Rating from Citi
Citi gave Cullinan Therapeutics a Buy rating with a $33 target, citing its cancer/autoimmune drug pipeline and key 2026 data readouts as a strong risk/reward opportunity.
/ 3 items
#CGEM↓
Guggenheim Initiates Buy on Cullinan Therapeutics with $30 Target
Guggenheim starts coverage on Cullinan Therapeutics with a Buy rating, citing promising Phase 1 data for T-cell engagers in autoimmune diseases and AML.
FDA Fast-Tracks New Blood Cancer Treatment CLN-049 for AML
Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.